Summary: The present study was designed to determine if the noncompetitive excitatory amino acid antagonist, dizocilpine maleate, when administered after a 17 min period of complete cerebral ischemia in primates, would improve postischemic neurologic function and hippocam pal histopathologic outcome when compared to placebo treated animals. Ten pigtail monkeys were anesthetized and subjected to complete cerebral ischemia using an es tablished neck tourniquet model. Five minutes postis chemia, five monkeys received dizocilpine 300 J.Lg/kg i. v. over 5 min, followed by an infusion of 150 J.Lg/kg/h for 10 h. This produced plasma levels of the drug in excess of 30 ng/ml for the duration of the infusion. An additional five monkeys were treated with an identical volume of saline placebo. All monkeys received intensive care for the ini-Recent research aimed at improving neurologic outcome following cerebral ischemia has focused on the role of excitatory amino acids. There is a large amount of experimental evidence supporting the hypothesis that postischemic neuronal necrosis may be caused in part by excessive activation of excitatory amino acid (EAA) transmitter systems (Olney, 1980; Jorgensen and Diemer, 1982; Cotman and Iverson, 1987 ). This excitotoxic model pro poses that the extracellular concentrations of en dogenous excitatory amino acid receptor agonists, such as L-glutamate and L-aspartate, are increased by ischemia. These EAAs then act to stimulate or tial 24 to 48 h postischemia. At 96 h postischemia, there was no significant difference in neurologic function be tween the two groups (p = 0.53, with the placebo group having the numerically better outcome). There also was no significant difference between hippocampal histopa thology scores between dizocilpine and placebo-treated monkeys. The authors conclude that dizocilpine is not an efficacious therapy in the treatment of neurologic injury that occurs following complete cerebral ischemia in this primate model. Key Words: Brain resuscitation Complete cerebral ischemia-Excitatory amino acid (EAA}-Excitatory amino acid antagonist-Dizocilpine maleate (MK-80 1 )-Hippocampal histopathology L-Glutamate antagonist-NMDA antagonist.
excite neurons possessing a high EAA receptor density and eventually cause neuronal death. Sup port for this hypothesis includes observations that ischemia does, in fact, result in a significant in crease in the extracellular concentrations of L glutamate and L-aspartate (Benveniste et aI., 1984; Hagburg et aI. , 1985) probably due to decreased reuptake of released EAAs (Drejer et al. , 1985) . Pro longed exposure of neurons to increased concentra tions of EAA receptor agonists such as L-glutamate, N-methyl-D-aspartate (NMDA), and kainate results in neuronal necrosis with rapid swelling presumably due to membrane depolarization, chloride influx, and subsequent water entry (Rothman, 1985; Olney et al. , 1986 ) and a slower necrosis thought to be secondary to increased calcium entry (Rothman and Olney, 1987) . In addition, it has long been appreci ated that short periods of cerebral ischemia result in a selective pattern of neuronal degeneration (Levine and Payan, 1966; Pulsinelli and Brierly, 1979; Brierly and Graham, 1984) . Areas of the brain that are the most vulnerable to ischemic damage, particularly the hippocampal layers CAl and CA2 and other limbic structures, are known to have a high density of the N-methyl-D-aspartate class of EAA receptors (Fagg and Foster, 1983; Monaghan and Cotman, 1986; Bowery et aI., 1988) .
EAA-mediated neurotoxicity can be attenuated by a variety of NMDA receptor antagonists (Simon et aI., 1984; Gerhardt et aI., 1986; Germano et aI., 1987) , of which the noncompetitive antagonist dizo cilpine maleate (previously known as MK-801; Merck Sharp & Dohme Laboratories) is the most potent and selective (Wong et aI., 1986; Kemp et aI., 1987) . Systemic administration of dizocilpine has resulted in postischemic neuronal sparing in the hippocampus of rabbits (Kochar et aI., 1988) , rats, and gerbils (Foster et aI., 1987; Gill et aI., 1987; McDonald et aI., 1987) . The latter work has shown that sparing of CA I neurons occurs whether dizo cilpine is given either before or as long as 24 h after an ischemic insult, a result that may have broad clinical significance. Recently, dizocilpine pretreat ment in cats was reported to decrease the volume of cortical ischemic damage following middle cerebral artery occlusion from 33 to 16% of the cerebral hemisphere (Ozyurt et aI., 1988) . In a subsequent study using the same cat model, Park et aI. (1988) also reported a decrease in ischemic cortical dam age when dizocilpine was given 2 h after the induc tion of focal ischemia.
At present, there are limited data examining the effects of dizocilpine on neurologic outcome follow ing complete cerebral ischemia. Using a canine model of complete cerebral ischemia in our labora tory, Michenfe1der et al. (1989) found that dizocil pine, when administered shortly after the ischemic episode, produced a numerical improvement in neurologic recovery; however, the numerical im provement was not statistically significant. We in terpreted those data as possibly suggestive of an improved outcome and therefore worthy of further investigation in a more sensitive model. Accord ingly, the present study was designed to examine the postischemic neurologic effects of dizocilpine given 5 min after 17 min of complete cerebral isch emia in an established primate model.
METHODS

Study subjects and preischemic preparation
This protocol was reviewed and approved by the Insti tutional Animal Care and Use Committee (IACUC). Twelve unmedicated male pigtail monkeys (Macaca nem-estrina) weighing 3.9-5.0 kg were studied. The monkeys were uniformly fed but received only water ad libitum the last 24 h before the experiment. Monkeys were initially anesthetized with halothane 2-4% inspired in oxygen in a plexiglass induction box. Pancuronium 2 mg and glyco pyrrolate 0.05 mg were given i.m. to facilitate tracheal intubation with a cuffed wire-spiral reinforced tube, and ventilation was controlled with a Harvard pump (Harvard Apparatus, Inc., Dover, MA, U.S.A.). For the remainder of the preparatory period, anesthesia was maintained with halothane 0.5% in 66% N20 and O2, Catheters were placed in the abdominal aorta via the femoral artery for blood sampling and pressure monitor ing and in a femoral and a peripheral vein for fluid and drug infusions. Additional doses of pancuronium 0.2 to 0.5 mg i.v. were given as needed. A two-channel EEG was recorded using bifrontal and biparietal needle elec trodes. Body temperature was measured with a rectal thermistor and maintained near 37°C throughout the ex periment using heating pads. End-tidal CO2 and inspired halothane concentrations were monitored with a mass spectrometer (Perkin-Elmer, Model 1100, Perkin-Elmer Corp., Pomona, CA, U.S.A.), and arterial blood gases were determined by electrodes (Instrumentation Labora tories, Inc., Lexington, MA, U.S.A.) at 37°C. Arterial blood gases were measured immediately preischemia and frequently postischemia. Plasma N a + and K + were mea sured pre ischemia and at 4 h intervals postischemia until extubation using a flame photometer (Instrumentation Laboratory Model 443). Blood glucose was determined by a membrane-bound enzyme technique (Yellow Springs Instruments Model 23A Glucose Analyzer, Yellow Springs, OH, U.S.A.). Blood glucose was measured fol lowing the preischemic dextrose infusion and frequently postischemia. All monkeys were initially hydrated with dextrose 5% in 0.45% saline solution (D5 Y 2 NS) 12 mllkg i.v. administered by an infusion pump over a 15 min pe riod. This dose of dextrose initially produced blood glu cose values of approximately 250 mg/dl, and ischemia was not produced until blood glucose had declined into the protocol range of <200 mg/di. Since blood glucose is known to affect neurologic outcome in this model (Lanier et aI., 1987) , and since monkey number 1 unexpectedly had a blood glucose of only 77 mg/dl at the time of pro duction of ischemia, in the remaining monkeys, if blood glucose declined below 150 mg/dl before ischemia was initiated, we elected to give a second infusion of D5 Y 2 NS at a rate of <30 mllh and a volume of < 15 mi. This ma neuver produced plateau blood glucose values at a target blood glucose range of 120 to 200 mg/di.
Production of ischemia
Complete cerebral ischemia was produced by a method previously described by Nemoto et al. (1977) and Bleyaert et ai. (1978) using modifications described by Steen et ai. (1985) . Halothane was discontinued for 3 min, and anesthesia was maintained with N20 66% in oxygen. Rapid induction of hypotension (within 1 min) was in duced by administration of trimethaphan 20-40 mg i. v. until a mean arterial pressure of approximately 50 mm Hg was achieved. At this point, a collapsible neck tourniquet was inflated to 1,500 mm Hg for 17 min, and the monkeys were ventilated with O2 enriched with 133Xe at 3 j.LCi/L during the period of cerebral ischemia. A tendency to hypertension during the first 5 min of ischemia was treated with additional administration of trimethaphan and the addition of positive end-expiratory airway pres-sure (PEEP) to maintain MAP near 40 mm Hg during the ischemic period. After one monkey (number 3) developed tachyphylaxis to trimethaphan and was lost from the pro tocol due to a failure to maintain blood pressure within the protocol guidelines during the ischemic period, we elected to add sodium nitroprusside (200 f.lg/ml) as a sec ondary drug for the treatment of blood pressure in the presence of trimethaphan tachyphylaxis. After 14 min of ischemia, a norepinephrine (NE) infusion was started at 0.4 f.lg/kg/min and adjusted as needed to maintain mean arterial pressure (MAP) at 80 mm Hg before neck tourni quet deflation. Immediately after tourniquet deflation, MAP always abruptly decreased. Further adjustments of the NE infusion were made to increase MAP to 80 to 110 mm Hg during the immediate postischemic period.
Completeness of cerebral ischemia was monitored us ing the EEG and was confirmed by the lack of detection of 133Xe over the cranium as previously described by Steen et al. (1985) .
Postischemic treatment
Five minutes postischemia, monkeys number 1-12 re ceived either dizocilpine 300 f.lg/kg i. v. over 5 min fol lowed by an infusion of 150 f.lg/kg/h for 10 h, or an equiv alent bolus and infusion volume of saline placebo accord ing to a randomized list. All personnel were blinded as to the treatment selection. The animals were studied in groups of four to six per week, and the randomization order was designed to have an equal distribution of dizo cilpine and placebo-treated monkeys after 6, 12, and pos sibly 20 monkeys had been studied. (It was also deter mined before the study began, and in accordance with the recommendation of the IACUC, that after 12 monkeys had been studied, the code would be broken. Based on the results in those monkeys, a decision would be made as to whether the study would continue.)
Optimal life support was provided for 24-48 h postis chemia as their condition demanded with a minimum of one technician and one physician in attendance. During the period of drug infusion, all monkeys were paralyzed with pancuronium and ventilation was controlled. Mon keys were ventilated with 100% Oz during the first 2 h, or until they had return of continuous EEG activity. There after, they received 50% NzO in Oz until shortly before extubation was attempted at 20 h postischemia. NzO, which has been shown to have no effect on outcome in this model (Gisvold et al., 1984) , provided analgesia and sedation during immobilization in an attempt to avoid a previously reported severe hypertensive reaction and to blunt any increases in cerebral blood flow (CBF) and me tabolism resulting from the stress of immobilization (Gis voId et ai., 1984; Tommasino and Shapiro, 1983) . PaCOz was maintained at 25-35 mm Hg and PaOz above 100 mm Hg by increasing FiOz as needed. A minimum of 2-3 cm of HzO PEEP was maintained during the intensive care period. Respiratory care included tracheal suctioning, in termittent deep lung inflations (sighing), chest physiother apy, and turning the monkeys from side to side every 4 h. At 20 h postischemia, the residual effects of the muscle relaxant pancuronium were reversed with neostigmine 0.07 mg/kg and glycopyrrolate 0.012 mg/kg i. v. Controlled ventilation was terminated and the endotracheal tube was removed if spontaneous ventilation was deemed ade quate, as judged by the presence of carinal and pharyn geal reflexes and maintenance of a PaOz "" 60 mm Hg and a PaCOz .:; 35 mm Hg.
J Cereb Blood Flow Metab, Vol. 10, No.2, 1990 MAP was maintained at 80--120 mm Hg during the first 20 h postischemia. This required a norepinephrine infu sion during the first hours postischemia. Trimethaphan (3-15 f.lg/kg/min) later was used as needed to avoid hy pertension. Dextrose 5% in 0.45% NaCI with 20 mEq/L KCl added was infused at 4 mllkg/h for the first 20 h (i.e., until extubation). If monkeys needed additional i.v. fluids during this period to assure hemodynamic stability and urine output at 0.5 mllkg/h, fluids were given in the form of lactated Ringer's solution in 10 ml/kg increments in fused over 1 h. After extubation, monkeys either received fluid as during the first 20 h, or were intermittently hy drated with 10--20 ml/kg of lactated Ringer's solution sub cutaneously, or were given fluids p.o. as determined by their activity and physical examination. Gentamicin 1.6 mg/kg i.m. was given every 8 h during the first 2 days. Benzathine penicillin 150,000 units and procaine penicil lin 150,000 units i.m. were given daily for 4 days. Diaze pam 0.1 mg/kg i. v. was given if necessary to treat sei zures.
When their physical status permitted, monkeys were returned to their cages. Every 8 h thereafter for the du ration of the study, the monkeys were examined, and, if needed, they were further hydrated.
Exclusions
Animals that did not meet all pre-established protocol criteria were excluded from data analysis before the final 96 h evaluation. The decision to exclude animals was made by a blinded observer (J.D.M.) who was unaware of treatment selection. Exclusion was based on strict crite ria: a preischemic blood glucose <50 or >200 mg/dl; ev idence of incomplete ischemia; severe cardiopulmonary complications such as pulmonary edema, resulting in a postischemic PaOz < 60 mm Hg and/or a PaCOz > 45 mm Hg; failure to achieve a postischemic MAP of >80 mm Hg within 3 min after cuff deflation; and, thereafter, a MAP <70 mm Hg for >60 min or of <50 mm Hg at any point, or a MAP> 130 mm Hg for more than 1 h.
Neurologic function postischemia
Neurologic function was evaluated at 26, 48, 72, and 96 h postischemia by the same blinded observer (J.D.M.). A previously described neurologic examination and scoring system were used (Steen et ai., 1985) . Briefly, this system assigned a score to monkeys according to their level of consciousness, respiration, cranial nerve function, motor and sensory function, and behavior. The results were ex pressed as percent neurologic function, where 100% was normal and 0% was apparent brain death.
Histopathologic evaluation
After the final clinical evaluation, the monkeys were reanesthetized with i.m. ketamine 5-20 mg/kg i.m., intu bated, and mechanically ventilated with room air. After performing a right thoracotomy, they were killed by in fusing 500 ml of 0.9% saline solution followed by 500 ml of 4% buffered paraformaldehyde into the left ventricle at a pressure of 100 mm Hg, with the descending thoracic aorta cross-clamped and the right atrium opened. One hour later, the brains were removed and placed in buff ered paraformaldehyde solution. All brains were fixed for 4 weeks prior to gross and microscopic examinations by a neuropathologist (B.W.S.) who was blind as to treatment selection. Coronal whole-mount, paraffin-embedded mi crosections were cut to a 6 f.lm thickness and were stained by the hematoxylin and eosin method. Because of the negative results in the neurologic outcome study, only the hippocampus was examined. The type and extent of his topathology was graded according to a previously de scribed scale (Steen et ai., 1985) . The severity of injury for both the fight and left hippocampus was assessed on a five-point scale: grade 0 (normal) = no ischemic changes; grade 1 (minimal damage) = the presence of rare single neurons showing either the eosinophilia typical of isch emic nerve cell change or frank necrosis; grades 2 (mod erate damage), 3 (severe damage), and 4 (maximal dam age) = the presence of ischemic nerve cell change or frank necrosis occurring in <25%, 25-50%, or >50% of neurons, respectively. (For representative photomicro graphs of the various grades, see Michenfelder et ai., 1989) .
Statistical evaluation
The significance of postischemic differences in neuro logic function and histopathology scores between the two groups was evaluated by the two-tailed Mann-Whitney rank sum test. Correlation between the neurologic func tion rank and histopathologic outcome rank was assessed by determining the Spearman rank correlation coeffi cient. Differences in physiologic variables were evaluated with the analysis of variance for repeated measures com bined with the Students-Newman-Keuls test. A proba bility of less than 0.05 was regarded as significant. All mean values are reported with the standard error of the mean.
High-dose dizocilpine pilot study
Based on the negative results of the initial study, a pilot study was performed in four monkeys to determine if the failure of dizocilpine to improve outcome in the initial study was based on insufficient drug dose. Monkeys were prepared, and ischemia was produced, in a manner iden tical to that in the initial study. Five minutes postis chemia, monkeys 13, 14, and 16 were given a bolus of dizocilpine 5 mg/kg over 5 min, followed by an infusion of 0.75 mg/kg/h for 10 h. Monkey 15 was given an iden tical volume of saline placebo. Dizocilpine drug concen trations were increased in this study so that the volume of drug and placebo would be identical to that used in the initial study. The treatment of monkeys in this pilot study differed from monkeys in the initial study in only two factors: (a) the total dose of dizocilpine was seven times greater, and (b) the pilot study was conducted in an un blinded fashion.
RESULTS
Five MK-801-and five placebo-treated monkeys fulfilled all protocol criteria and therefore were in cluded in the final analysis.
Exclusions
Two monkeys (numbers 3 and 10) were excluded from the study for failure to maintain complete isch emia during the period of tourniquet inflation. Mon key number 3 was randomized to placebo treat ment, and number 10 was randomized to dizocilpine treatment. In both, incomplete ischemia was iden tified by an increase from baseline in cranial gamma activity, indicating the presence of 133 Xe in the cra nial circulation. Only in the latter monkey was the persistence of EEG activity noted, and this was of a low amplitude. Both monkeys were excluded from the protocol immediately upon confirming a proto col violation and were killed shortly thereafter.
Study group match
The dizocilpine-vs. placebo-treated groups were well matched for body weight (4.3 ± 0. 2 kg in each group) and preischemic physiologic variables (Ta ble l). There were no significant differences be tween study groups in blood gases, acid-base sta tus, MAP, temperature, blood glucose, or electro lytes when measured preischemia or postischemia. Preischemic blood glucose was 146 ± 19 mg/dl in the placebo-treated group and 153 ± 9 mg/dl in the dizocilpine group (NS = not statistically signifi cant). MAP returned to 80 mm Hg at 30 ± 8 vs. 13 ± 5 s postischemia in dizocilpine-vs. placebo treated monkeys, respectively (NS). There were no apparent dizocilpine-related hemodynamic effects All values are mean ± SEM . There were no significant differences between groups .
as subjectively judged by those providing postisch emic care for the monkeys.
Completeness of ischemia
With the exception of the two monkeys described in the "Exclusions" section, all monkeys had EEG and scintillation detector evidence of complete isch emia. With neck tourniquet inflation, there was loss of EEG activity within seconds, and no 133 Xe was detected by the cranially apposed scintillation probe. In all ten subjects included in the final data analysis, there was a sharp increase in cranial ra dioactivity occurring within seconds after tourni quet deflation.
Plasma levels of dizocilpine
Plasma levels of dizocilpine had a peak value of 73 ± 5 ng/mg 5 min after the bolus dose (Table 2) . Thereafter, mean plasma drug levels were in excess of 30 ng/ml during the 10 h infusion period. Dizo cilpine plasma levels had decreased to 3 ± 1 ng/ml at the 24 h measurement period. Dizocilpine was not detected in the plasma of placebo-treated mon keys, or in the plasma during the preischemic con trol period of any monkey.
Seizure activity
In one dizocilpine-treated monkey (number 9), the EEG returned as bursts of sharp waves at 15 h postischemia. By 17 h 40 min postischemia, there was continuous EEG activity consisting of polyspike and wave complexes of 1-2 s duration and a frequency of every 3 s superimposed on a background of delta activity. This monkey contin ued to have EEG and clinical evidence of seizures that were partially refractory to diazepam therapy throughout the 96 h study period. This monkey had a 96 h neurologic function score of 40, the worst outcome of any monkey in the study.
Neurologic outcome
There was no significant difference between neu rologic outcome in dizocilpine-vs. placebo-treated monkeys (Fig. 1) . When compared by Mann Whitney rank sum test, data achieved a p = 0.53, with placebo monkeys having the numerically bet ter outcome. Only one monkey had a normal neu rologic exam at 96 h postischemia. This monkey received placebo treatment and also had the lowest blood glucose value at the onset of ischemia of any monkey studied.
Histopathology scoring
There was no significant difference in the histo pathology scores between the dizocilpine-and pla cebo-treated groups for either CAl or CAz , 3 , 41ayers of the hippocampus (Figs. 2 and 3) . In both groups, the reported score was calculated as the average of the left and right hemisphere scores.
In general, there was a good correlation between histopathology score ranks and neurologic outcome ranks, regardless of the treatment group. The Spearman rank correlation coefficient between neu rologic function rank and histopathology rank was rs = 0.61 for the CAl layer (0.1 > P > 0.05) and rs = 0.82 for the CAz , 3 , 4 layer (p < 0.01).
High-dose dizocilpine pilot study
The results of the high-dose dizocilpine pilot study are summarized in Table 3 , and they will be briefly reviewed. Monkey number 13 experienced a sudden, witnessed cardiac arrest at 9.6 h postis chemia. Immediately before the arrest, there was a sudden decrease in mean arterial blood pressure without a decrease in heart rate. The monkey was rapidly resuscitated with cardiac compression and norepinephrine 0.24 mg i.v. The EEG initially re turned in bursts containing sharp waves; however, it later deteriorated to an isoelectric EEG. The monkey was later declared brain dead when he was disconnected from the ventilator and failed to at tempt spontaneous breathing. Monkeys number 14 and 16 also received dizocilpine; there was, how ever, no hemodynamic instability observed in these animals. Both required intensive care for 48 h, and monkey 16 required ventilator support for 32 h and intubation for 57 h. The prolonged intensive care support in these two monkeys was presumably due to the sedative effects of MK-801 and the poor neu rologic recovery. Upon reversing pancuronium induced paralysis, monkey number 14 exhibited tonoclonic activity that persisted for most of the entire 96 h study period. An EEG performed during
.E .� I "":. ""!. this interval revealed spike and wave activity. Both monkeys 14 and 16 had severe neurologic deficits, with 96 h neurologic function scores of 58 and 43%, respectively. There was no detectable dizocilpine in the plasma of monkey 14 at 96 h to account for its poor scoring. Monkey 16 had a 96 h dizocilpine level of 2 ng/ml. Monkey 15 (placebo-treated) had an uneventful postischemic course. EEG activity returned much earlier in this animal than in the di zocilpine-treated pilot monkeys, and he was extu bated and returned to his cage earlier. His 96 h neu rologic function score was 55%, a score that was within the range observed for control monkeys in the initial study.
DISCUSSION
Dizocilpine had no beneficial effect whatsoever on neurologic outcome in monkeys following 17 min of complete cerebral ischemia, and, in fact, the out come of dizocilpine-treated monkeys was numeri cally -but not significantly-worse than that of placebo-treated monkeys (p = 0.53). There were no significant differences between groups in factors such as body temperature, hemoglobin, age, blood gases, acid-base status, or hemodynamics that could account for the failure of dizocilpine to im prove outcome. The failure of dizocilpine to im prove outcome also occurred using a drug dosage regimen that resulted in plasma levels in excess of 30 ng/ml. These plasma levels are slightly greater than the levels of 25 ng/ml previously demonstrated to produce hippocampal sparing in laboratory ani mals (unpublished data, Merck Sharp & Dohme Laboratories). Despite apparently adequate plasma blood levels in our study, we demonstrated neither hippocampal sparing nor improvement in neuro logic function.
Prior to beginning this study, there were several published reports supporting the hypothesis that di zocilpine would improve hippocampal histopathol ogy following cerebral ischemia; however, there were no data supporting the hypothesis that func tional outcome following complete cerebral isch emia would be improved. In a canine study from our laboratory, Michenfelder et al. (1989) examined the effects of dizocilpine on functional outcome and hippocampal histopathology following com plete ischemia. In that study, five of nine dogs were normal 72 h after exposure to 11 min of complete cerebral ischemia followed by doses of dizocilpine sufficient to produce plasma levels >25 ng/rnl. How ever, in the control group, there was an unexpected incidence of normal animals as well (three of nine). Accordingly, the suggested improvement in out- Cardiac arrest at 9.6 h postischemia come by dizocilpine was not statistically significant.
Despite the failure to demonstrate a statistically sig nificant change by dizocilpine, we believed the re sults were sufficiently promising to proceed with the present primate study. Also, in our canine study, we noted no statistically significant improve ment in hippocampal histopathology by dizocilpine treatment; however, there was a significant corre lation between functional outcome and histopathol ogy scores. This suggested that hippocampal histo pathology may be a valid indicator of ultimate neu rologic function whether or not the subjects got dizocilpine. We were concerned that the failure of our canine study to demonstrate an improvement in outcome may have been influenced by the lack of sophistication in the model used, causing possible subtle neurologic differences to be overlooked. Thus, the present primate study was performed. Our results did not support the continuation of fur ther studies at the drug dosage initially agreed upon. Of the 12 monkeys studied at the lower drug dose, 10 fulfilled all protocol criteria for inclusion in the results. The Mann-Whitney rank sum test demon strated that placebo-treated monkeys had a numer ically better outcome than dizocilpine-treated mon keys at the p = 0.53 level. The neurologic function scoring system used in our study is clearly more sensitive to cortical than to hippocampal function. In two recent studies in cats using a middle cerebral artery occlusion model of focal ischemia, it was found that dizocilpine 5 mg/kg resulted in a significant decrease in the vol ume of the injured cerebral cortex, and the benefi cial effect of dizocilpine occurred regardless of whether the drug was given before (Ozyurt et aI., 1988) or 2 h after (Park et aI., 1988 ) the induction of ischemia. It is possible, then, that a dose of dizo cilpine greater than that used in our initial study would be required to demonstrate improved general cortical function and neurologic functional recovery in our primate model. Based on this consideration, we examined the effect of a higher dose of dizo cilpine on neurologic injury in a brief pilot study. The severe postischemic neurologic and histopath ologic injury in those monkeys suggested no im provement by dizocilpine; thus, we concluded that the lack of beneficial effect of dizocilpine in our initial study was not based on inadequate drug dose. The failure of dizocilpine to improve outcome in the primate model we used may be explained best by the following rationale: It has recently been ob served that dizocilpine may offer neuronal protec tion from ischemic injury in some animal models, but not in others. As reviewed by Siesjo and Bengtsson (1989) , cerebral protection by NMDA antagonists appears to be unequivocally present in two types of animal models: middle cerebral artery occlusion and hypoglycemic coma. In contrast, the neuroprotective effects of NMDA antagonists are equivocal in a gerbil model of transient, bilateral carotid artery occlusion. Finally, neuroprotection appears to be absent in two types of rat models: a four-vessel occlusion model producing dense fore brain ischemia, and a model of two-vessel occlusion combined with hypotension. These results suggest that NMDA antagonists are neuroprotective when an ischemic insult is less dense (e.g., as occurs with focal ischemia), or when ATP depletion is partial (e.g., as occurs with hypoglycemic coma). It is pos sible, then, that the protective effects of NMDA antagonists are inversely correlated with the mag nitude of high-energy metabolite depletion intro duced by an ischemic or hypoglycemic injury.
This hypothesis has recently been presented by Siesjo and Bengtsson (1989) , and will be briefly re viewed. It is thought that the predominant mecha-nism by which EAAs influence ischemic neuronal injury is by causing a pathologic calcium influx through the NMDA receptor-gated channel. Thus, once an NMDA agonist binds with a postsynaptic receptor, the result is an influx of calcium. Under normal circumstances (i.e., when energy is avail able), this postsynaptic response is terminated by reuptake of the EAA transmitter, and by extrusion of calcium from the cell by means of Ca 2 + and N a + /K + -dependent ATPase transport systems. This process also restores the normal concentra tions of N a + , K + , and CI-. However, if the energy stores of the cell have been depleted, EAA trans mitter reuptake and calcium extrusion will be de creased, and calcium entry via the NMDA receptor gated pathways will be pathologically sustained. These conditions may result in neuronal injury. It is possible that noncompetitive NMDA antagonists such as dizocilpine block calcium pathways during certain types of ischemia, thus producing a reduc tion in calcium-mediated injury. However, in order for the protective mechanism to be operative, ATP must be present as a source of energy to fuel ion pumps and maintain ion gradients. It is hypothe sized that with hypoglycemia or in the perifocal "penumbra" zone of an infarct produced by middle cerebral artery occlusion, the energy stores of neu rons are sufficient to allow the NMDA antagonists to decrease beneficially the pathologic calcium in fluxes. In contrast, in the presence of more severe forms of brain ischemia (e.g., as occurs with the four-vessel occlusion model in rats), it is hypothe sized that intracellular calcium achieves a threshold level that permits the opening of calcium-permeable nonselective cation channels. This in turn will result in a further-and potentially deleterious-increase in intracellular calcium. Because calcium entry un der such circumstances might occur predominantly through nonspecific cation channels rather than through the NMDA receptor-gated channel, the ad ministration of an NMDA antagonist would not be expected to prevent the calcium fluxes or attenuate postischemic neuronal injury. Data from our labo ratory examining the effects of dizocilpine therapy on outcome following complete cerebral ischemia in dogs (Michenfelder et aI., 1989) as well as the result of the present study using a primate model of com plete cerebral ischemia are consistent with the pro posal that NMDA antagonists will not provide neu ronal protection when cellular energy depletion is severe.
In the present studies, two of the dizocilpine treated monkeys (one receiving the smaller dose of dizocilpine and one receiving the larger dose) had persistent postischemic seizure activity. Seizures are a known complication of ischemic neurologic injury, including that produced by the neck tourni quet model we used (Steen et aI., 1985) . Dizocil pine has previously been demonstrated to have an tiepileptic properties, preventing bicuculline induced seizures in rats and electroshock-induced seizures in mice (Cline schmidt et aI., 1982) . How ever, in a recent study by Perkins et aI. (1989) , di zocilpine produced quasiperiodic bursts of 100--200 fL V delta waves and polyspikes on a background of low amplitude beta activity in normal dogs. The al tered EEG activity was not observed when dizo cilpine was given 1 h after an 11 min period of isch emia, a time in which the dogs had either an iso electric EEG (N = 4) or a low amplitude, low frequency EEG. The authors did not study the ef fects of administration of dizocilpine for prolonged periods after the return of EEG activity, a situation that would be more comparable to the conditions of our present primate study. However, the findings of epileptiform activity in normal dogs given dizo cilpine is similar to the EEG effects of phencycli dine and ketamine (Kayama and Iwama, 1972; Corssen et aI., 1974; Contreras et aI., 1986) . Both of the latter drugs, like dizocilpine, are noncompeti tive NMDA receptor antagonists (Anis et aI., 1983; Thomson et aI., 1985; Wong et aI., 1986; Foster and Wong, 1987; Loo et aI., 1987) . In addition, ketamine is reported to produce epileptic activity in some set tings (Kayama and Iwama, 1972; Corssen et aI., 1974; Contreras et aI., 1986; Perkins et aI., 1989) , but inhibit epileptic activity in other settings (Cors sen et aI., 1974; Cline schmidt et aI., 1982) . Thus, it is unclear in the setting of the present study whether dizocilpine influenced the presence of seizures. It is also unclear whether the extremely poor neurologic outcomes of the two monkeys that seized were due to severe ischemia producing the seizures, or whether the seizure activity resulted in an increased severity of neurologic injury.
In conclusion, the present study demonstrated that dizocilpine does not improve postischemic neu rologic functional recovery of hippocampal histopa thology in monkeys when given 5 min after a 17 min period of complete cerebral ischemia. This failure to improve outcome occurred even though serum drug concentrations were in excess of 30 ng/ml for prolonged periods. Based on these data, we con clude that dizocilpine, when administered as de scribed in the present study, is not an efficacious therapy for treatment of neurologic injury that oc curs following complete cerebral ischemia. 
